CG Oncology, Inc. (CGON)
NASDAQ (NGS) NASDAQ (NGS) Primary 
CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
CGON expects phase III PIVOT-006 top-line data in first-half 2026, nearly a year early, after enrollment finished ahead of schedule across more than 90 sites.
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene
CG Oncology maintains a "Strong Buy" rating, driven by significant pipeline progress and multiple upcoming catalysts in 2026. Completion of the rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC and potential FDA acceptance are key near-term catalysts in 2026. Early enrollment completion in the phase 3 PIVOT-006 trial for IR-NMIBC accelerates topline data to 1H 2026, positioning the company for a potential first FDA approval in this segment.
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.3 per share a year ago.
CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?
CG Oncology remains a compelling buy, driven by strong phase 3 data for its oncolytic virus therapy in bladder cancer. CGON's lead candidate, cretostimogene grenadenorepvec, achieved a 41.8% complete response rate at 24 months in high-risk NMIBC patients. CGON boasts a robust cash runway, supporting ongoing trials and potential regulatory delays, but FDA approval is not guaranteed and competition is intensifying.
CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
CG Oncology, Inc. (NASDAQ:CGON ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Arthur Kuan - Chairman & CEO Ambaw Bellete - President & COO Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Okay. Good morning, everyone, and welcome to Morgan Stanley Global Healthcare Conference.
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)
CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash position, providing a multi-year runway and reducing near-term dilution risk as it approaches potential commercialization. Key risk remains the lack of randomized data for FDA approval, but I view the likelihood of approval as high given the compelling clinical results.
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74.5% CR rate in the BOND-003 trial and a 41.2% CR rate in a phase 1 trial for MIBC. A basic DCF valuation estimates CGON's enterprise value at $5.3bn, suggesting a price target of $69, about 3x the current price.
